知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

4 records (took 0.01 seconds)

    Use of fructose-based compounds for the diagnosis of cancer
    1.
    发明授权
    Use of fructose-based compounds for the diagnosis of cancer 有权
    使用果糖类化合物诊断癌症

    公开(公告)号：US08241607B2

    公开(公告)日：2012-08-14

    申请号：US12064496

    申请日：2006-08-24

    Applicant: Anthony P. Heaney ,  Hongxiang Hui ,  Alan Waxman

    Inventor： Anthony P. Heaney ,  Hongxiang Hui ,  Alan Waxman

    IPC: A61K49/00

    CPC classification number: C12N15/1137 ,  A01K2267/0331 ,  C12N15/1138 ,  C12N2310/14 ,  C12Y202/01001 ,  C12Y207/01001 ,  C12Y207/01004 ,  C12Y401/02013

    Abstract: This invention relates to compositions, methods utilizing fructose and other monosaccharides for the diagnosis of cancer. Cancer cells have shown a higher level of fructose utilization as compared to glucose. Further, cancer cells have shown a preferential use of fructose for nucleic acid synthesis. The present invention takes advantage of these features and provides for fructose or fructose-based compositions for the diagnosis of cancer using imaging techniques such as positron emission tomography.

    Abstract translation: 本发明涉及使用果糖和其他单糖用于诊断癌症的组合物。 与葡萄糖相比，癌细胞显示出更高水平的果糖利用。 此外，癌细胞已经显示出优先使用果糖用于核酸合成。 本发明利用这些特征并提供使用成像技术如正电子发射断层扫描的用于诊断癌症的果糖或果糖类组合物。

    Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
    2.
    发明授权
    Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1 失效

    公开(公告)号：US07141240B2

    公开(公告)日：2006-11-28

    申请号：US10097230

    申请日：2002-03-12

    Applicant: Riccardo Perfetti ,  Hongxiang Hui

    Inventor： Riccardo Perfetti ,  Hongxiang Hui

    IPC: A61K48/00 ,  A01N63/00 ,  C12N15/63 ,  C12N5/00 ,  C12N5/06 ,  C12N15/85

    CPC classification number: A61K38/26 ,  A61K48/00 ,  A61K48/0058 ,  C07K14/605

    Abstract: Disclosed herein are cells that secrete insulin in a glucose-dependent manner. The cell line comprises insulin-secreting cells that have been transfected with a minigene construct comprising a nucleotide sequence encoding for glucagon-like peptide-1 (GLP-1). In preferred embodiments, the minigene construct is operatively associated with a promoter. The cell line may be used to treat diabetes or other conditions in which delivering insulin in a glucose-dependent manner would be advantageous, to investigate the function and development of pancreatic cells, and to test the efficacy of drugs that stimulate insulin secretion. The cells may be implanted in a mammal, or may be included in a device that resides exterior to the mammal, yet which delivers insulin to the mammal in response to the glucose level of a body fluid in contact therewith. The minigene construct may also be implemented in conjunction with an in vivo gene transfer approach.

Patent Agency Ranking